Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04193813
Other study ID # El-Manial Hospital
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 15, 2018
Est. completion date May 23, 2019

Study information

Verified date May 2020
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

There are a wide range of significant epidemiological, clinical, and operative predictors for the development of post-CABG AF including older age, female gender, large LA diameter, higher CHA2DS2-VASc score, valve replacement and postoperative inotropic support. Nevertheless, further large-scale studies are still needed to confirm our findings


Description:

We included patients undergoing isolated CABG or CABG with (Aortic and / or Mitral) valve replacement with an age group between 18 and 70 years old.

Patients diagnosed preoperatively with AF or have history of AF, patients with history of existing pre-operative rhythm other than normal sinus rhythm (NSR), patients with impaired systolic function (Ejection fraction (EF) < 30%), patients with end stage renal disease (ESRD) on hemodialysis and patients who refused to participate in the study were excluded from the study.

Sample Size and Sampling: Using PASS program, setting alpha error at 5% and power 80%. Results from previous study Ducceschi et al. (6) showed that left atrial (LA) diameter was an independent factor affecting AF post CABG. Based on this, the needed sample was 123 cases undergoing CABG, including at least 24 patients with dilated LA.

All individuals were monitored for AF during the postoperative ICU stay with continuous ECG (5-leads) monitor, daily 12-lead ECG recording to confirm an episode of AF. AF was considered if P wave was absent before the QRS complex together with irregular ventricular rhythm on the rhythm strips.

Only AF episodes lasting > 5 minutes were counted. In the present study, the following data, as potential predictors of POAF, was collected from every eligible participant; age, sex, smoking and left atrial (LA) diameter based on formal preoperative Trans-thoracic Echocardiography. Serum potassium (K+) level was routinely measured postoperatively on ICU admission and every 2 hours and on demand (if arrhythmia occurs or suspected abnormal potassium level). It was recorded for statistical analysis on admission and every 12 hours and on demand until the patient was discharged.

Serum Magnesium (Mg++) level was measured routinely measured postoperatively on ICU admission and every 24 hours and on demand (if arrhythmia occurs or suspected abnormal magnesium level). It was recorded for statistical study on admission and every 24 hours and on demand until the patient was discharged.

Other parameters such as valve replacement (Aortic and/or Mitral) during the same operative setting, CHA2DS2-VASc score (Congestive heart failure, Hypertension [blood pressure >140/90 mm Hg or treated hypertension on medication], Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, vascular disease, Age 65 to 74 years, Sex category [female sex] ), and post-operative inotropic support usage were recorded.


Recruitment information / eligibility

Status Completed
Enrollment 123
Est. completion date May 23, 2019
Est. primary completion date March 18, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients undergoing isolated CABG

- Patients undergoing CABG with (Aortic and / or Mitral) valve replacement

- age group between 18 and 70 years old.

Exclusion Criteria:

- Patients diagnosed preoperatively with AF or have history of AF

- Patients with history of existing pre-operative rhythm other than normal sinus rhythm (NSR)

- Patients with impaired systolic function (Ejection fraction (EF) < 30%)

- Patients with end stage renal disease (ESRD) on hemodialysis

- Patients who refused to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational
Observational study

Locations

Country Name City State
Egypt Hanaa El Gendy Cairo Ain Shams University Specialized Hospital

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of POAF Incidence of POAF 72hours postoperative 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05841615 - Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN) N/A
Recruiting NCT03750435 - Non-fluoroscopy Ablation of AF/AT N/A
Recruiting NCT04577859 - Oesophageal Protection Study: A Multicentre Study. N/A
Not yet recruiting NCT05168189 - the Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome